NorthStrive Launches Preclinical EL-32 Study to Assess Muscle Preservation in Obesity Mouse Model
PMGC subsidiary NorthStrive has launched a preclinical diet-induced obesity mouse study of EL-32 to evaluate lean muscle preservation and fat mass reduction with and without semaglutide. The finalized study design, timeline and budget cover months of dosing, observation and analysis, with outcomes guiding potential follow-on development.
1. Preclinical Study Launch
NorthStrive Biosciences, a subsidiary of PMGC Holdings, has initiated a diet-induced obesity mouse study for its engineered probiotic candidate EL-32. The program marks the first in vivo evaluation of EL-32’s potential to preserve lean muscle while promoting fat loss.
2. Study Objectives
The study is designed to assess changes in body weight, fat mass, lean muscle preservation and glycemic markers. Multiple treatment groups will compare standalone EL-32 administration against combination dosing with semaglutide, a leading GLP-1 receptor agonist.
3. Timeline and Budget
With study planning finalized, the program allocates several months for preclinical dosing, physiological observations and data collection. A contracted research organization will handle dosing protocols, data analysis and reporting within the established budget.
4. Development Outlook
Preclinical outcomes are expected to inform potential follow-on studies and refine development strategy. Positive results could position EL-32 as a complementary therapy to GLP-1 weight loss treatments targeting muscle preservation.